Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 20/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.68 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.68 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.68 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.68 |
| ▸ | MLNR | O43193 | 1/20 | 0.68 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.68 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | PGR | P06401 | 1/20 | 0.68 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.68 |
| ▸ | HTR1A | P08908 | 1/20 | 0.68 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28927601 | 1.00 | CYP3A4 (0.68) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL22123754 | 1.00 | CYP3A4 (0.68) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL22123751 | 0.87 | CYP3A4 (0.68) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL22364323 | 0.86 | CYP3A4 (0.74) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL971609 | 0.86 | CYP3A4 (0.74) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL17745131 | 0.86 | CYP3A4 (0.74) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL4951603 | 0.84 | CYP3A4 (0.77) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL2913540 | 0.82 | CYP3A4 (0.77) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL8269408 | 0.82 | CYP3A4 (0.77) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL17742222 | 0.82 | CYP3A4 (0.77) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140343062-A1 | METHOD OF TREATING A VIRAL INFECTION USING ELVITEGRAVIR COMBINATIONS | GILEAD SCIENCES, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8889153-B2 | Combination of immunomodulator and anti-pathogenic agent | NUNES ISEU DA SILVA (BR) | 2014-11-18 | — | — | US | disclosed |
| US-20110028385-A1 | Combination of Immunomodulator and Anti-Pathogenic Agent | NUNES ISEU DA SILVA | 2011-02-03 | — | — | US | disclosed |
| US-20110009411-A1 | THERAPEUTIC COMPOSITIONS AND THE USE THEREOF | GILEAD SCIENCES ,INC. (CA) | 2011-01-13 | — | — | US | disclosed |
| US-20090093482-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | GILEAD SCIENCES, INC. (US) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093482-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | ACE, ACE2, CCR5 | CYP3A4 78/4885CYP2D6 51/4885CYP2C9 394/4885 |
| US-20140343062-A1 | METHOD OF TREATING A VIRAL INFECTION USING ELVITEGRAVIR COMBINATIONS | CCR5, ZC3HAV1, ABL1 | CYP3A4 13/4885CYP2D6 37/4885CYP2C9 157/4885 |
| US-20110009411-A1 | THERAPEUTIC COMPOSITIONS AND THE USE THEREOF | ACE, FURIN, CCR5 | CYP3A4 75/4885CYP2D6 113/4885CYP2C9 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.